EMA Authorised: Signifor (pasireotide) — Recordati Rare Diseases

View source ↗

Summary

The EMA authorised Signifor (pasireotide) for acromegaly and pituitary ACTH hypersecretion. Recordati Rare Diseases is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Cushing Disease

Drugs mentioned

• SIGNIFOR (PASIREOTIDE)

Snippet

Status: Authorised. Therapeutic area: Acromegaly;Pituitary ACTH Hypersecretion. MAH: Recordati Rare Diseases. Decision date: 16/12/2024